Unlocking the body's secret weapon against lung cancer
Some of the medical breakthroughs happen when we finally notice something that has always been there but we missed it. That is what happened at WEHI. Researchers at WEHI identified a type of cell that had quietly been able to detect and destroy small cell lung cancer , one of the most aggressive and hardest-to-treat cancers. The discovery, published in Cancer Cell showed that patients who had more of these cells survived significantly longer. This opens a path for a disease that has not progressed much in decades.
Why this cancer has been so hard to beat
Small cell lung cancer is harsh in ways less than seven percent of patients survive five years after diagnosis. Immunotherapy has changed treatment for other cancers, but it has not worked well for small cell lung cancer. This is mainly because small cell lung cancer hides well. The tumors often slip past the immune cells that most immunotherapy treatments depend on, allowing the disease to keep growing even while the immune system is on alert.
The immune cell that sees through the disguise
The cells behind this discovery are called gamma delta T cells . Professor Kate Sutherland, the author of the study says gamma delta T cells can see through the cancers usual camouflage. She noted that researchers have known for decades that small cell lung cancer hides well but gamma delta T cells can spot it anyway. Strikingly patients whose tumors had gamma delta T cells had noticeably better treatment outcomes. This gives researchers evidence that gamma delta T cells are truly fighting this disease from inside.
Testing it in the lab
To see this in action, researchers built tumors in the lab using real tissue donated by patients. This created one of the most realistic laboratory models of small cell lung cancer. When they added gamma delta T cells taken from the patients' blood, the results were striking. The immune cells were highly effective at finding and destroying the cancer cells.
Researchers then tested two existing medicines to see if they could make this response stronger. Zoledronate , already used for bone problems, and tarlatamab , an approved cell lung cancer medicine, were used. Zoledronate increased the number of gamma delta T cells. Sharpened their ability to find tumors. Tarlatamab helped bring gamma delta T cells and cancer cells physically. When used together, the two medicines greatly increased the cancer‑killing power of gamma delta T cells in the lab.
What this could mean for patients?
Dr. Jin Ng, the author of the study, says this discovery could lead to a treatment where a patient's own immune cells are collected, multiplied outside the body, and returned in larger numbers to fight the cancer better. This is already technically possible today. For patients who have numbers of gamma delta T cells, medicines such as zoledronate could help increase their numbers and improve their overall response to treatment.
Researchers also traced the fingerprints of this pathway through two major trials, IMpower133 and CASPIAN. They found that patients with gamma delta T cell activity responded better to immunotherapy overall. The WEHI team is now working with the Doherty Institute to move this discovery toward a class of treatment. This could finally give hope for small cell lung cancer, a cancer that has resisted progress for too long.
Why this cancer has been so hard to beat
Small cell lung cancer is harsh in ways less than seven percent of patients survive five years after diagnosis. Immunotherapy has changed treatment for other cancers, but it has not worked well for small cell lung cancer. This is mainly because small cell lung cancer hides well. The tumors often slip past the immune cells that most immunotherapy treatments depend on, allowing the disease to keep growing even while the immune system is on alert.
The immune cell that sees through the disguise
The cells behind this discovery are called gamma delta T cells . Professor Kate Sutherland, the author of the study says gamma delta T cells can see through the cancers usual camouflage. She noted that researchers have known for decades that small cell lung cancer hides well but gamma delta T cells can spot it anyway. Strikingly patients whose tumors had gamma delta T cells had noticeably better treatment outcomes. This gives researchers evidence that gamma delta T cells are truly fighting this disease from inside.
Testing it in the lab
To see this in action, researchers built tumors in the lab using real tissue donated by patients. This created one of the most realistic laboratory models of small cell lung cancer. When they added gamma delta T cells taken from the patients' blood, the results were striking. The immune cells were highly effective at finding and destroying the cancer cells.
Researchers then tested two existing medicines to see if they could make this response stronger. Zoledronate , already used for bone problems, and tarlatamab , an approved cell lung cancer medicine, were used. Zoledronate increased the number of gamma delta T cells. Sharpened their ability to find tumors. Tarlatamab helped bring gamma delta T cells and cancer cells physically. When used together, the two medicines greatly increased the cancer‑killing power of gamma delta T cells in the lab.
What this could mean for patients?
Dr. Jin Ng, the author of the study, says this discovery could lead to a treatment where a patient's own immune cells are collected, multiplied outside the body, and returned in larger numbers to fight the cancer better. This is already technically possible today. For patients who have numbers of gamma delta T cells, medicines such as zoledronate could help increase their numbers and improve their overall response to treatment.
Researchers also traced the fingerprints of this pathway through two major trials, IMpower133 and CASPIAN. They found that patients with gamma delta T cell activity responded better to immunotherapy overall. The WEHI team is now working with the Doherty Institute to move this discovery toward a class of treatment. This could finally give hope for small cell lung cancer, a cancer that has resisted progress for too long.
Next Story